Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393131 | 0.89 | ALDH1A1 (0.47) | ALDH1A1GAAARSLC6A3MAPT | |
| SCHEMBL10379316 | 0.83 | L3MBTL1 (0.46) | ALDH1A1GAASLC6A3MAPTL3MBTL1 | |
| SCHEMBL1418785 | 0.83 | ALDH1A1 (0.44) | ALDH1A1GAASLC6A3MAPTLMNA | |
| SCHEMBL2647143 | 0.82 | LMNA (0.43) | ALDH1A1SLC6A3LMNAKDM4EL3MBTL1 | |
| SCHEMBL2646980 | 0.82 | L3MBTL1 (0.44) | SLC6A3L3MBTL1POLBKMT2AMEN1 | |
| SCHEMBL2644774 | 0.81 | SLC6A2 (0.53) | ALDH1A1GAASLC6A3LMNAKDM4E | |
| SCHEMBL11038742 | 0.81 | MAPT (0.54) | ALDH1A1GAAARMAPTLMNA | |
| SCHEMBL2646165 | 0.81 | GCK (0.44) | ALDH1A1SLC6A3LMNAPOLBKMT2A | |
| SCHEMBL11932079 | 0.80 | SLC6A3 (0.54) | ALDH1A1GAASLC6A3MAPTLMNA | |
| SCHEMBL13839179 | 0.79 | CYP19A1 (0.47) | ALDH1A1SLC6A3KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2554540-A2 | 3-Cyclyl-2-(4-sulfamoyl-phenyl)-n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | Novartis AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| EP-1934180-B1 | 3-CYCLYL-2-(4-SULFAMOYL-PHENYL)-N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES | NOVARTIS AG (CH) | 2012-12-05 | — | — | EP | disclosed |
| US-8252931-B2 | Thiazolo[5,4-B]pyridine glucokinase activators | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| EP-1934233-B1 | SULFONAMIDE DERIVATIVES AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES | NOVARTIS AG (CH) | 2012-05-16 | — | — | EP | disclosed |
| EP-1735322-B1 | SULFONAMIDE-THIAZOLPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS USEFUL FOR THE TREATMENT OF TYPE 2 DIABETES | NOVARTIS AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| EP-2298779-A1 | Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes | Novartis AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| CN-1960995-B | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes | NOVARTIS AG | 2010-12-08 | — | — | CN | disclosed |
| US-7795257-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7750020-B2 | 3-Cyclopentyl-2-(4-cyclopropylsulfamoyl-phenyl)-N-(5-methoxy-thiazolo[5,4-b]pyridin-2-yl)-propionamide; antidiabetic agent; insulin resistance, impaired glucose tolerance, obesity; with other hypolipidemic agent, anti-obesity and hypotensive agent | NOVARTIS AG (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20080318948-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-6489485-B2 | INCREASES INSULIN SECRETION; TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-12-03 | — | — | US | disclosed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | disclosed |
| US-20010051731-A1 | Para-amine substituted phenylamide glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-12-13 | — | — | US | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| WO-2001085707-A1 | PARA-AMINE SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | GCKR, GCK, PDXK | ALDH1A1 2470/4885GAA 103/4885AR 2492/4885 |
| US-20080318948-A1 | Organic Compounds | GCK, GCKR, SLC2A2 | ALDH1A1 236/4885GAA 83/4885AR 3449/4885 |
| US-20010051731-A1 | Para-amine substituted phenylamide glucokinase activators | GCKR, GCK, PDXK | ALDH1A1 3015/4885GAA 82/4885AR 3186/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | ALDH1A1 3111/4885GAA 384/4885AR 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.